Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today reported recent corporate highlights and its financial results for the second quarter ended June 30, 2014.
“We have achieved all of our anticipated milestones in the quarter, most notably the reporting of positive results from our two clinical-stage programs derived from our ATLAS™ platform,” said Chip Clark, president and chief executive officer of Genocea. “We remain on track to advance these programs and to provide a compelling cadence of milestones and data over the next twelve months.”
Help employers find you! Check out all the jobs and post your resume.
